In this paper we put forward the claim that the combination of low dose-rate brachytherapy (BRT) and fractionated external-beam radiotherapy (EBRT) may, when planned to take advantage of the relative advantages of each of these two modalities, result in enhanced tumor dose with no penalties to organs at risk. The concept of iso-effective dose (IED) serves the role of common currency for fusing BRT and EBRT and, for evaluation purposes, converting back the resulting IED distribution into a biologically equivalent plan delivered by any single modality. If we accept this view, there are further questions that must be answered regarding practical matters. We show how to deal with these questions by describing an actual patient plan.

Keywords:

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

1 Ragde H, Korb L, Elgamal AA: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma – reply. Cancer85,1205–1206 (1999).
Google Scholar
2 Lee Sp, Leu MY, Smathers JB, McBride WH, Parker RG, Withers HR: Biologically effective dose distribution based on the linear-quadratic model and its clinical relevance. Int. J. Radiat. Oncol. Biol. Physics33,375–389 (1995).
Medline CASGoogle Scholar
3 Wang JZ, Li XA: Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med. Phys.30,34–40 (2003).
Medline CASGoogle Scholar
4 Zaider M, Zelefsky MJ, Cohen GN et al.: Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.61,702–713 (2005).•• Detailed description of treatment planning concepts for combined brachytherapy– external-beam radiotherapy (see figure 2).
MedlineGoogle Scholar
5 Zaider M, Happersett L, Cohen G, Chui C, Yorke E, Zelefsky M: The role of external beam in brachytherapy. Med. Phys.33,2258 (2006).
Google Scholar
6 Martinez AA, Kestin LL, Stromberg JS et al.: Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont Phase II dose-escalating trial. Int. J. Radiat. Oncol. Biol. Phys.47,343–352 (2000).
Medline CASGoogle Scholar
7 Martinez AA, Gustafson G, Gonzalez J et al.: Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.53,316–327 (2002).
MedlineGoogle Scholar
8 Martinez A, Gonzalez J, Spencer W et al.: Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J. Urol.169,974–980 (2003).
MedlineGoogle Scholar
9 Vargas CE, Martinez AA, Boike TP et al.: High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a Phase I to II study. Int. J. Radiation Oncol. Biol. Phys.66,416–423 (2006).• Clinical results for high-dose-rate boost in treating prostate cancer.
MedlineGoogle Scholar
10 Li XJZ, Pamea DS: Using IMRT to repair unacceptable dose distributions of prostate implants (abstract). Int. J. Radiat. Oncol. Biol. Phys.57,S434 (2003).
MedlineGoogle Scholar
11 Zaider M, Rossi HH: The synergistic effects of different radiations. Radiat. Res.83,732–739 (1980).• First demonstration that radiation effects interact synergistically.
Medline CASGoogle Scholar
12 Zaider M: There is no mechanistic basis for the use of the linear-quadratic expression in cellular survival analysis. Med. Phys.25,791–792 (1998).• Sobering message for the aficionados of the linear-quadratic formalism.
Medline CASGoogle Scholar
13 Lea DE, Catcheside DG: The mechanism of the induction by radiation of chromosome aberrations in tradescantia. J. Genetic44,216–245 (1942).•• This is the original paper describing the dose-effect function; generally not credited by the numerous workers who have ‘rediscovered’ Lea and Catcheside’s result.
Google Scholar
14 Kellerer AM, Rossi HH: Generalized formulation of dual radiation action. Radiat. Res.75,471–88 (1978).•• Provides a mechanistic (microdosimetric-based) explanation of the linear quadratic model for chromosomal aberrations. Should be required reading for biophysicists.
Google Scholar
15 Rossi HH, Zaider M: Current topics in dual radiation action. Radiat. & Environ. Biophys.27,221 (1988).
Google Scholar
16 Zaider M, Dicello J, Beoer R: A Fortran program for the computation of RBEs, OERs, survival ratios and the effects of fractionation using the theory of dual radiation action. Los Alamos Scientific Laboratory Report LA-7196-MS, 1–19 (1978).
Google Scholar
17 Dale RG: The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Brit. J. Radiol.58,515–528 (1985).
Medline CASGoogle Scholar
18 Wuu CS, Zaider M: A mathematical-description of sublethal damage repair and interaction during continuous low dose-rate irradiation. Radiat. Prot. Dosimetry52,211–215 (1994).
Google Scholar
19 Brenner DJ, Hall EJ. Conditions for the equivalence of continuous to pulsed low-dose rate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys.20,181–190 (1991).
Medline CASGoogle Scholar
20 Zaider M, Minerbo GN: Tumour control probability: a formulation applicable to any temporal protocol of dose delivery. Phys. Med. Biol.45,279–293 (2000).•• For the mathematically inclined, this paper contains the derivations of the expressions used in this review article.
Google Scholar
21 Zaider M, Zelefsky MJ, Hanin LG, Tsodikov AD, Yakovlev AY, Leibel SA: A survival model for fractionated radiotherapy with an application to prostate cancer. Phys. Med. Biol.46,2745–2758 (2001).
Google Scholar
22 Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W: Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiation Oncol. Biol. Phys.46,839–850 (2000).
Medline CASGoogle Scholar
23 Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W: 10-year biochemical (prostate-specific antigen) control of prostate cancer with I-125 brachytherapy. Int. J. Radiat. Oncol. Biol. Phys.51,31–40 (2001).
Medline CASGoogle Scholar
24 Haustermans KMG, Hofland I, Van Poppel H et al.: Cell kinetic measurements in prostate cancer. Int. J. Radiat.Oncol. Biol. Phys.37,1067–1070 (1997).• Provides a flavor of the variability of cell-proliferation parameters for prostate cancer.
Medline CASGoogle Scholar
25 Spirou SV, Chui CS: Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators. Med. Phys.21,1031–1041 (1994).
Medline CASGoogle Scholar
26 Zelefsky MJ, Fuks Z, Happersett L et al.: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother. Oncol.55,241–249 (2000).
Medline CASGoogle Scholar
27 Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Brit. J. Radiol.62,679–694 (1989).
Medline CASGoogle Scholar
28 Dale RG: Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model. Brit. J. Radiol.62,241–244 (1989).
Medline CASGoogle Scholar

Vol. 3, No. 2

Metrics

Downloaded 87 times

History

Published online 26 March 2007

Published in print April 2007

Information

Keywords

PDF download

The role of external beam in brachytherapy

Abstract

Bibliography